

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

### Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 years and over [ID2704]

#### Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Companies</u></p> <ul style="list-style-type: none"> <li>• Ultragenyx (Evinacumab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Addenbrookes Liver Transplant Association</li> <li>• Blood Pressure UK</li> <li>• British Cardiac Patients Association</li> <li>• British Liver Trust</li> <li>• Cardiac Risk in the Young</li> <li>• Cardiovascular Care Partnership</li> <li>• Children’s Liver Disease Foundation</li> <li>• Circulation Foundation</li> <li>• Different Strokes</li> <li>• Gene People</li> <li>• Genetic Alliance UK</li> <li>• HEART UK</li> <li>• Liver4Life</li> <li>• Pulmonary Hypertension Association UK</li> <li>• Pumping Marvellous Foundation</li> <li>• Somerville Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Stroke Association</li> <li>• Stroke Information</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Genetic Nurses &amp; Counsellors</li> <li>• British and Irish Hypertension Society</li> <li>• British Association for the Study of the Liver</li> <li>• British Association for Nursing in Cardiovascular Care</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Cell and Gene Therapy Catapult</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Diabetes UK Cymru</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Government</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Amgen (evolocumab)</li> <li>• Amryt Pharmaceuticals DAC (lomitapide)</li> <li>• Aurobindo Pharma – Milpharm (ezetimibe)</li> <li>• Daiichi Sankyo UK (ezetimibe)</li> <li>• Glenmark Pharmaceuticals Europe (ezetimibe)</li> <li>• Organon Pharma UK (ezetimibe)</li> <li>• Sandoz (ezetimibe)</li> <li>• Zentiva (ezetimibe)</li> </ul>

Final stakeholder list for the evaluation of evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over ID2704.

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• British Association of Endocrine and Thyroid Surgeons</li> <li>• British Association of Stroke Physicians</li> <li>• British Atherosclerosis Society</li> <li>• British Cardiovascular Society</li> <li>• British Dietetic Association</li> <li>• British Society of Paediatric Gastroenterology, Hepatology and Nutrition</li> <li>• British Heart Foundation</li> <li>• British Inherited Metabolic Disease Group</li> <li>• British Nuclear Cardiology Society</li> <li>• British Society for Gene and Cell Therapy</li> <li>• British Society for Genetic Medicine</li> <li>• British Society for Haematology</li> <li>• British Society for Haemostasis and Thrombosis</li> <li>• British Society for Heart Failure</li> <li>• British Society for Paediatric Endocrinology and Diabetes</li> <li>• British Society of Cardiovascular Imaging</li> <li>• British Thoracic Society</li> <li>• Clinical Leaders of Thrombosis</li> <li>• National Heart and Lung Institute</li> <li>• National Metabolic Biochemistry Network</li> <li>• Neonatal and Paediatric Pharmacists Group</li> <li>• Primary Care Cardiovascular Society</li> <li>• Royal College of Emergency Medicine</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Paediatrics and Child Health</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society for Cardiological Science &amp; Technology</li> <li>• Society for Endocrinology</li> <li>• Society for Vascular Nurses</li> <li>• Society for Vascular Technology</li> </ul>	<p data-bbox="847 248 1219 277"><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Society for Cardiovascular Research</li> <li>• Cardiac and Cardiology Research Department, Barts</li> <li>• Circulation Foundation</li> <li>• Cochrane Cystic Fibrosis &amp; Genetic Disorders Group</li> <li>• Cochrane Heart Group</li> <li>• Cochrane Hypertension Group</li> <li>• Cochrane Metabolic &amp; Endocrine Disorders Group</li> <li>• Cochrane Stroke Group</li> <li>• Cochrane UK</li> <li>• European Council for Cardiovascular Research</li> <li>• Genomics England</li> <li>• Heart Research UK</li> <li>• MRC Clinical Trials Unit</li> <li>• National Centre for Cardiovascular Preventions and Outcomes</li> <li>• National Institute for Cardiovascular Outcomes Research</li> <li>• National Institute for Health Research</li> <li>• Wellcome Trust</li> </ul> <p data-bbox="847 1238 1321 1267"><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• TREND Diabetes</li> <li>• UK Clinical Pharmacy Association</li> <li>• Vascular Society of Great Britain &amp; Ireland</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts

---

<sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.